Search

Your search keyword '"Assenat, E."' showing total 390 results
Start Over Author "Assenat, E."
390 results on '"Assenat, E."'

1. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma

Author

Fraunhoffer, N., Hammel, P., Conroy, T., Nicolle, R., Bachet, J.-B., Harlé, A., Rebours, V., Turpin, A., Ben Abdelghani, M., Mitry, E., Biagi, J., Chanez, B., Bigonnet, M., Lopez, A., Evesque, L., Lecomte, T., Assenat, E., Bouché, O., Renouf, D.J., Lambert, A., Monard, L., Mauduit, M., Cros, J., Iovanna, J., and Dusetti, N.

Published
2024
Full Text
View/download PDF

2. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Author

Kelley, RK, Gane, E, Assenat, E, Siebler, J, Galle, PR, Merle, P, Hourmand, IO, Cleverly, A, Zhao, Y, Gueorguieva, I, Lahn, M, Faivre, S, Benhadji, KA, and Giannelli, G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Clinical Trials and Supportive Activities, Liver Cancer, Liver Disease, Rare Diseases, Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Administration, Oral, Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular, Case-Control Studies, Disease Progression, Drug Therapy, Combination, Female, Humans, Liver Neoplasms, Male, Middle Aged, Protein Kinase Inhibitors, Pyrazoles, Quinolines, Receptors, Transforming Growth Factor beta, Safety, Sorafenib, Transforming Growth Factor beta1, Treatment Outcome, alpha-Fetoproteins, Clinical sciences
Abstract

IntroductionInhibition of tumor growth factor-β (TGF-β) receptor type I potentiated the activity of sorafenib in preclinical models of hepatocellular carcinoma (HCC). Galunisertib is a small-molecule selective inhibitor of TGF-β1 receptor type I, which demonstrated activity in a phase 2 trial as second-line HCC treatment.MethodsThe combination of galunisertib and sorafenib (400 mg BID) was tested in patients with advanced HCC and Child-Pugh A liver function without prior systemic therapy. Galunisertib dose was administered 80 or 150 mg b.i.d. orally for 14 days every 28 days in safety lead-in cohorts; in the expansion cohort, all patients received galunisertib 150 mg b.i.d. Objectives included time-to-tumor progression, changes in circulating alpha fetoprotein and TGF-β1, safety, overall survival (OS), response rate, and pharmacokinetics (PK).ResultsPatients (n = 47) were enrolled from 5 non-Asian countries; 3 and 44 patients received the 80 mg and 150 mg b.i.d. doses of galunisertib, respectively. The pharmacokinetics and safety profiles were consistent with monotherapy of each drug. For the 150 mg b.i.d. galunisertib cohort, the median time-to-tumor progression was 4.1 months; the median OS was 18.8 months. A partial response was seen in 2 patients, stable disease in 21, and progressive disease in 13. TGF-β1 responders (decrease of >20% from baseline) vs nonresponders had longer OS (22.8 vs 12.0 months, P = 0.038).DiscussionThe combination of galunisertib and sorafenib showed acceptable safety and a prolonged OS outcome.

Published
2019

5. Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC)

Author

Rafii, H., Frère, C., Benzidia, I., Crichi, B., Andre, T., Assenat, E., Bournet, B., Carpentier, A., Connault, J., Doucet, L., Durant, C., Emmerich, J., Gris, J.C., Hij, A., Le Hello, C., Madelaine, I., Messas, E., Ndour, A., Villiers, S., Marjanovic, Z., Ait Abdallah, N., Yannoutsos, A., and Farge, D.

Published
2020
Full Text
View/download PDF

7. Chimiothérapie par oxaliplatine normalisée à la quantité de masse maigre pour des cancers du côlon de stade III traités en adjuvant : impact sur les neurotoxicités à partir d’une étude randomisée multicentrique de phase II (LEANOX)

Author

Assenat, E., primary, Ben Abdelghani, M., additional, Monnier, M., additional, Perrier, H., additional, Khemissa, F., additional, Desgrippes, R., additional, Galais, M., additional, Rinaldi, Y., additional, Lepage, C., additional, and Senesse, P., additional

Published
2023
Full Text
View/download PDF

9. 83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Author

Chan, S.L., primary, Kudo, M., additional, Sangro, B., additional, Kelley, R.K., additional, Furuse, J., additional, Park, J-W., additional, Sunpaweravong, P., additional, Fasolo, A., additional, Yau, T., additional, Kawaoka, T., additional, Cheng, A-L., additional, Azevedo, S., additional, Reig Monzon, M.E., additional, Assenat, E., additional, Yarchoan, M., additional, He, A.R., additional, Makowsky, M., additional, Ran, D., additional, Negro, A., additional, and Abou-Alfa, G.K., additional

Published
2022
Full Text
View/download PDF

10. 67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Author

Chan, S.L., primary, Kudo, M., additional, Sangro, B., additional, Kelley, R.K., additional, Furuse, J., additional, Park, J-W., additional, Sunpaweravong, P., additional, Fasolo, A., additional, Yau, T., additional, Kawaoka, T., additional, Cheng, A-L., additional, Azevedo, S., additional, Reig Monzon, M.E., additional, Assenat, E., additional, Yarchoan, M., additional, He, A.R., additional, Makowsky, M., additional, Gupta, C., additional, Negro, A., additional, and Abou-Alfa, G.K., additional

Published
2022
Full Text
View/download PDF

11. LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Author

Qin, S., primary, Kudo, M., additional, Meyer, T., additional, Finn, R.S., additional, Vogel, A., additional, Bai, Y., additional, Guo, Y., additional, Meng, Z., additional, Zhang, T., additional, Satoh, T., additional, Hiraoka, A., additional, Marino, D., additional, Assenat, E., additional, Wyrwicz, L., additional, Campos, M. Calvo, additional, Hsing-Tao, K., additional, Boisserie, F., additional, Li, S., additional, Chen, Y., additional, and Zhu, A.X., additional

Published
2022
Full Text
View/download PDF

12. 714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Author

Chan, L.S., primary, Kudo, M., additional, Sangro, B., additional, Kelley, R.K., additional, Furuse, J., additional, Park, J-W., additional, Sunpaweravong, P., additional, Fasolo, A., additional, Yau, T., additional, Kawaoka, T., additional, Cheng, A-L., additional, Azevedo, S., additional, Reig Monzon, M.E., additional, Assenat, E., additional, Yarchoan, M., additional, He, A.R., additional, Makowsky, M., additional, Ran, D., additional, Negro, A., additional, and Abou-Alfa, G.K., additional

Published
2022
Full Text
View/download PDF

13. Hépatites auto-immunes induites par inhibiteurs de checkpoints : étude observationnelle CHILI

Author

Hountondji, L., primary, Palassin, P., additional, Faure, S., additional, Iltache, S., additional, Dupuy, M., additional, Pageaux, G.P., additional, Faillie, J.L., additional, Lesage, C., additional, Negre, E., additional, Assenat, E., additional, Rullier, P., additional, Rivet, V., additional, Quantin, X., additional, Meunier, L., additional, and Maria, A., additional

Published
2022
Full Text
View/download PDF

14. P-19 Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)

Author

Merle, P., primary, Edeline, J., additional, Fang, W., additional, Assenat, E., additional, Pan, H., additional, Rimassa, L., additional, Li, Z., additional, Blanc, J., additional, Yen, C., additional, Ross, P., additional, Hu, S., additional, Zhang, T., additional, Tran, A., additional, Shao, G., additional, Bouattour, M., additional, Chen, Y., additional, Wu, J., additional, Li, B., additional, Chica-Duque, S., additional, and Ren, Z., additional

Published
2022
Full Text
View/download PDF

22. LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

Author

Conroy, T., primary, Hammel, P., additional, Turpin, A., additional, Belletier, C., additional, Wei, A., additional, Mitry, E., additional, Lopez, A., additional, Francois, E., additional, Artru, P., additional, Biagi, J., additional, Lecomte, T., additional, Assenat, E., additional, Faroux, R., additional, Ychou, M., additional, Bouche, O., additional, Lambert, A., additional, Monard, L., additional, Rat, P., additional, Castan, F., additional, and Bachet, J-B., additional

Published
2021
Full Text
View/download PDF

23. The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown

Author

rinaldi y, dossantos m, ychou m, andre t, smith d, botsen d, delafouchardiere c, Bouche O, Alain R. Thierry, assenat e, gavoille c, mazard t, linot b, vanbockstael J, ellis s, sefrioui d, dominguez s, pezzella, fonck M, clavel l, martin-Babau j, guardiola e, ghiringhelli F, francois e, Caroline Mollevi, khemissa f, Brice Pastor, and pisareva e

Subjects
Oncology, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Colorectal cancer, business.industry, Tumor burden, Cancer, medicine.disease, Clinical trial, Median follow-up, Internal medicine, Cohort, medicine, business, Survival rate
Abstract

BackgroundThe COVID-19 pandemic led to a significant reduction in the provision of screening, case identification and hospital referrals to cancer patients. To our knowledge, no study has yet correlated quantitatively the consequences of these limitations for cancer patient management. This study evaluates the implications of such reductions for patients newly diagnosed with metastatic colorectal cancer (mCRC) in both the pre- and post-lockdown periods.MethodsWe examined 80 newly identified mCRC patients from 18 different clinical centers. These cases come from the screening procedure of a clinical trial which is using circulating DNA (cirDNA) analysis to determine their RAS and BRAF status.ResultsThe tumor burden as evaluated by the median total plasma cirDNA concentration showed a statistically higher level in patients diagnosed post-lockdown compared to those diagnosed pre-lockdown (119.2 versus 17.3 ng/mL; pConclusionsRecognizing that our exploratory study offers a snapshot of an evolving situation, our observations nonetheless clearly highlight the need to determine actions which would minimize delays in diagnosis during the ongoing and future waves of COVID-19.

Published
2021

24. O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma

Author

Ducreux, M., primary, Abou-Alfa, G., additional, Ren, Z., additional, Edeline, J., additional, Li, Z., additional, Assenat, E., additional, Rimassa, L., additional, Blanc, J., additional, Ross, P., additional, Fang, W., additional, Hu, S., additional, Zhang, T., additional, Tran, A., additional, Pan, H., additional, Yen, C., additional, Wu, J., additional, Li, V., additional, Chica-Duque, S., additional, Merle, P., additional, and Cheng, A., additional

Published
2021
Full Text
View/download PDF

25. Facteurs pronostiques des myocardites induites par les inhibiteurs du checkpoint immunologique

Author

Coustal, C., primary, Quantin, X., additional, Lesage, C., additional, Michot, J.M., additional, Laparra, A., additional, Ederhy, S., additional, Assenat, E., additional, Faure, M., additional, Issa, N., additional, Lambotte, O., additional, Puyade, M., additional, Dereure, O., additional, Rullier, P., additional, Serre, I., additional, Klouche, K., additional, Vernhet, H., additional, Faillie, J.L., additional, Roubille, F., additional, Guilpain, P., additional, and Maria, A., additional

Published
2021
Full Text
View/download PDF

26. Gestion des toxicités induites par les inhibiteurs de checkpoint immunologique : données de la RCP « ToxImmun » en Occitanie Est

Author

Rivet, V., primary, Quantin, X., additional, Faillie, J.L., additional, Lesage, C., additional, Meunier, L., additional, Faure, S., additional, Hillaire-Buys, D., additional, Lesouder, C., additional, Fabre, S., additional, Assenat, E., additional, Rullier, P., additional, Guilpain, P., additional, and Maria, A., additional

Published
2021
Full Text
View/download PDF

28. 121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium

Author

Delaunay, B., Hollebecque, A., Bouattour, M., Blanc, J.F., Assenat, E., Turpin, A., Sarabi, M., Roth, G., Tougeron, D., Edeline, J., Ben Abdelghani, M., Vienne, A., Hiret, S., Artru, P., Stacoffe, M., Malka, D., Neuzillet, C., Lievre, A., Guimbaud, R., and Fares, N.

Published
2023
Full Text
View/download PDF

30. The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown

Author

Thierry, AR, primary, Pastor, B, additional, Pisareva, E, additional, Ghiringhelli, F, additional, Bouche, O, additional, De La Fouchardière, C, additional, Vanbockstael, J, additional, Smith, D, additional, François, E, additional, Dos Santos, M, additional, Botsen, D, additional, Ellis, S, additional, Fonck, M, additional, Andre, T, additional, Guardiola, E, additional, Khemissa, F, additional, Linot, B, additional, Martin-Babau, J, additional, Rinaldi, Y, additional, Assenat, E, additional, Clavel, L, additional, Dominguez, S, additional, Gavoille, C, additional, Sefrioui, D, additional, Pezzella, V, additional, Mollevi, C, additional, Ychou, M, additional, and Mazard, T, additional

Published
2021
Full Text
View/download PDF

41. Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)

Author

Kudo, M., primary, Galle, P.R., additional, Motomura, K., additional, Assenat, E., additional, Merle, P., additional, Brandi, G., additional, Daniele, B., additional, Okusaka, T., additional, Tomasek, J., additional, Borg, C., additional, Zagonel, V., additional, Morimoto, M., additional, Pracht, M., additional, Finn, R.S., additional, Llovet, J., additional, Homma, G., additional, Jen, M.-H., additional, Shinozaki, K., additional, Yoshikawa, R., additional, and Zhu, A.X., additional

Published
2019
Full Text
View/download PDF

42. Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis

Author

Llovet, J., primary, Kudo, M., additional, Kang, Y.-K., additional, Yen, C.-J., additional, Finn, R.S., additional, Galle, P.R., additional, Assenat, E., additional, Motomura, K., additional, Okusaka, T., additional, Berg, T., additional, Hsu, C.-H., additional, Ikeda, M., additional, Hsu, Y., additional, Liang, K., additional, Widau, R., additional, Schelman, W., additional, O’Brien, L., additional, Gao, L., additional, and Zhu, A.X., additional

Published
2019
Full Text
View/download PDF

43. Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Author

Zhu, A.X., primary, Galle, P.R., additional, Llovet, J.M., additional, Finn, R.S., additional, Kang, Y.-K., additional, Yen, C.J., additional, Assenat, E., additional, Brandi, G., additional, Motomura, K., additional, Ohno, I., additional, Daniele, B., additional, Vogel, A., additional, Yamashita, T., additional, Hsu, C.-H., additional, Meyer, T., additional, Widau, R., additional, Schelman, W., additional, Wang, C., additional, Hsu, Y., additional, and Kudo, M., additional

Published
2019
Full Text
View/download PDF

45. LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

Author

Walter, T.A., Lievre, A., Coriat, R., Malka, D., El Hajbi, F., Di Fiore, F., Dhome, O. Hentic, Smith, D., Hautefeuille, V., Roquin, G., Perrier, M., Dahan, L., V. Granger, Sobhani, I., Mineur, L., Niccoli, P., Assenat, E., Le Malicot, K., Lepage, C., and Bohas, C. Lombard

Published
2022
Full Text
View/download PDF

46. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Author

Meyer, T., primary, Finn, R., additional, Kudo, M., additional, Kang, Y., additional, Yen, C., additional, Galle, P., additional, Llovet, J., additional, Assenat, E., additional, Brandi, G., additional, Motomura, K., additional, Okusaka, T., additional, Hubner, R., additional, Karwal, M., additional, Baron, A., additional, Ikeda, M., additional, Liang, K., additional, Wang, C., additional, Widau, R., additional, Schelman, W., additional, and Zhu, A., additional

Published
2019
Full Text
View/download PDF

47. Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients

Author

Samalin, E., primary, Mazard, T., additional, Assenat, E., additional, Rouyer, M., additional, De la Fouchardière, C., additional, Guimbaud, R., additional, Smith, D., additional, Portales, F., additional, Ychou, M., additional, Fiess, C., additional, de Forges, H., additional, Lopez-Crapez, E., additional, and Thézenas, S., additional

Published
2019
Full Text
View/download PDF

48. Abstract No. 526 CheckMate-9DX: phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Author

Exposito, M. Jimenez, primary, Akce, M., additional, Alvarez, J., additional, Assenat, E., additional, Balart, L., additional, Baron, A., additional, Decaens, T., additional, Heurgue-Berlot, A., additional, Martin, A., additional, Paik, S., additional, Poulart, V., additional, Sehbai, A., additional, Shimada, M., additional, Takemura, N., additional, and Yoon, J., additional

Published
2019
Full Text
View/download PDF

50. CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Author

Jimenez Exposito, M.J., primary, Akce, M., additional, Alvarez, J.L.M., additional, Assenat, E., additional, Balart, L.A., additional, Baron, A.D., additional, Decaens, T., additional, Heurgue-Berlot, A., additional, Martin, A.O., additional, Paik, S.W., additional, Poulart, V., additional, Sehbai, A.S., additional, Shimada, M., additional, Takemura, N., additional, and Yoon, J.-H., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results